These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 7976677)
1. Low dose spironolactone in the treatment of female hyperandrogenemia and hirsutism. Vĕtr M; Sobek A Acta Univ Palacki Olomuc Fac Med; 1993; 135():55-7. PubMed ID: 7976677 [TBL] [Abstract][Full Text] [Related]
3. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Kazerooni T; Dehghan-Kooshkghazi M Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of spironolactone in polycystic ovary syndrome. Milewicz A; Silber D; Kirschner MA Obstet Gynecol; 1983 Apr; 61(4):429-32. PubMed ID: 6828272 [TBL] [Abstract][Full Text] [Related]
5. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Mazza A; Fruci B; Guzzi P; D'Orrico B; Malaguarnera R; Veltri P; Fava A; Belfiore A Nutr Metab Cardiovasc Dis; 2014 Feb; 24(2):132-9. PubMed ID: 23845740 [TBL] [Abstract][Full Text] [Related]
6. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Musso C; Cochran E; Javor E; Young J; Depaoli AM; Gorden P Metabolism; 2005 Feb; 54(2):255-63. PubMed ID: 15690321 [TBL] [Abstract][Full Text] [Related]
7. Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome. Evans DJ; Burke CW J R Soc Med; 1986 Aug; 79(8):451-3. PubMed ID: 3761287 [TBL] [Abstract][Full Text] [Related]
8. Spironolactone for hirsutism in polycystic ovary syndrome. Christy NA; Franks AS; Cross LB Ann Pharmacother; 2005 Sep; 39(9):1517-21. PubMed ID: 16076921 [TBL] [Abstract][Full Text] [Related]
9. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. Gökmen O; Senöz S; Gülekli B; Işik AZ Gynecol Endocrinol; 1996 Aug; 10(4):249-55. PubMed ID: 8908525 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study. Karakurt F; Sahin I; Güler S; Demirbas B; Culha C; Serter R; Aral Y; Bavbek N Adv Ther; 2008 Apr; 25(4):321-8. PubMed ID: 18389188 [TBL] [Abstract][Full Text] [Related]
11. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Wu J; Zhu Y; Jiang Y; Cao Y Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522 [TBL] [Abstract][Full Text] [Related]
12. Effect of spironolactone on testosterone and LHRH responsiveness in women with polycystic ovarian disease. Evron S; Yosef SM; Schenker JG; Diamant YZ Isr J Med Sci; 1984 Jul; 20(7):630-3. PubMed ID: 6432730 [No Abstract] [Full Text] [Related]
13. [Treatment of hirsutism with spironolactone and with spironolactone plus dexamethasone]. Devoto E; Aravena L; Ríos R Rev Med Chil; 2000 Aug; 128(8):868-75. PubMed ID: 11129548 [TBL] [Abstract][Full Text] [Related]
14. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression. Elkind-Hirsch KE; Anania C; Malinak R J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188 [TBL] [Abstract][Full Text] [Related]
15. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907 [TBL] [Abstract][Full Text] [Related]
16. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases]. Song J; Shen H; Li J; Huang Z; Zhang Y Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071 [TBL] [Abstract][Full Text] [Related]
17. Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study. Prabhakar S; Sahota P; Kharbanda PS; Siali R; Jain V; Lal V; Khurana D Epilepsia; 2007 Jul; 48(7):1371-7. PubMed ID: 17441994 [TBL] [Abstract][Full Text] [Related]
18. Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome. Narsing Rao L; Jacob JJ; Paul TV; Rajarathinam S; Thomas N; Seshadri MS J Pediatr Adolesc Gynecol; 2009 Apr; 22(2):91-5. PubMed ID: 19345914 [TBL] [Abstract][Full Text] [Related]
19. Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOS. Cupisti S; Dittrich R; Binder H; Kajaia N; Hoffmann I; Maltaris T; Beckmann MW; Mueller A Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):380-6. PubMed ID: 17701884 [TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism. Hassa H; Tanir HM; Yildiz Z Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]